Low-dose decitabine for previously untreated acute myeloid leukemia ineligible for intensive chemotherapy aged 65 years or older: a prospective study based on comprehensive geriatric assessment.

ABSTRACT:

Background

The outcome of patients with acute myeloid leukemia (AML) aged ⩾65 years is poor. Effective treatment options are limited for patients with AML who cannot tolerate intensive chemotherapy.

Objectives

We aimed to evaluate the efficacy of low-dose decitabine in previously untreated patients with AML aged ⩾65 years who were ineligible for intensive chemotherapy based on a comprehensive geriatric assessment.

Design

We performed a prospective, multicenter, open-label, and non-randomized study.

Methods

Patients were enrolled at four centers in Beijing between 1 January 2017 and 31 December 2020. They were treated with decitabine at a dose of 6 mg/m² for 10 days. The treatment was repeated every 28 days for one cycle for a total of six cycles. The

SUBMITTER: Feng R 

PROVIDER: S-EPMC10685783 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature